Expert consensus on surgical technique for subretinal injection of gene therapy in China

Title: Expert consensus on surgical technique for subretinal injection of gene therapy in China
Edition: Original
Classification: Experts consensus
Field: Treatment
Countries and regions: China
Guidelines users:
Evidence classification method: Not Applicable
Development unit: 中华医学会眼科学分会眼底病学组;中国医师协会眼科医师分会眼底病专业委员会
Registration time: 2022-06-18
Registration number: IPGRP-2022CN349
Purpose of the guideline: With the introduction of landmark genetic product, Luxturna, into clinical application, gene therapy is widely development in ophthalmology. Subretinal injection technique has become one of the important methods to treat inherited retinal diseases (IRDs) and other fundus diseases. The efficacy of gene therapy, distribution of viral vector and immune response mainly depend on the safe and efficient delivery of drugs into the subretinal space. The subretinal injection of gene therapy is characterized by the addition of unique drug delivery opeartion on the basis of vitreoretinal surgery, so that the therapeutic gene can accurately reach the target. Currently, IRDs gene therapy has just started in China. Therefore, it is necessary to develop a detailed and complete surgical procedure for subretinal injection of gene therapy according to the current domestic and abroad clinical practice. The protocol may facilitate the development of gene therapy related to IRDs and fundus diseases. With the development of genetic technology, the relevant content will be constantly updated.